HERLYSTIC trademark application for HER2 cancer treatment
The USPTO received trademark application TM99431686 for HERLYSTIC, filed October 7, 2025, covering pharmaceutical preparations targeting the HER2 protein for cancer treatment. The application is filed as Intent-to-Use, indicating the applicant plans to commercialize the mark in the future. This is an informational notice of a trademark filing in Class 005 (pharmaceuticals).
BECZELTEV Trademark Application for Pharmaceutical Preparations
USPTO received trademark application TM99424865 for the word mark "BECZELTEV" filed October 2, 2025. The application is classified under Class 5 (pharmaceutical preparations) and covers goods for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. This is an Intent-to-Use application, indicating the applicant plans to use the mark in commerce but has not yet done so.
CMS 1135 Waiver Request - Paperwork Reduction Act Notice
CMS published a notice under the Paperwork Reduction Act announcing a 60-day public comment period on a revision to the existing 1135 Waiver Request information collection (OMB Control No. 0938-1384). The collection supports the Acute Hospital Care at Home (AHCAH) program. Comments are due by June 1, 2026.
Microcyn Intent-to-Use Trademark Application for Disinfectant Products
USPTO received an intent-to-use trademark application for 'MICROCYN' (Serial No. TM99323863) covering all-purpose disinfectants and disinfectants for medical, dental, and veterinary instruments. The application was filed by Microcyn on August 6, 2025. This filing does not grant trademark rights until the mark is used in commerce.
VIAMEND trademark renewal for bone void fillers
The USPTO renewed the VIAMEND trademark (Registration TM90191559) for bone void fillers consisting of biological materials. The trademark was originally filed on September 18, 2020, and the renewal was processed on March 30, 2026. This is a routine trademark maintenance action with no new obligations imposed on the trademark holder or affected manufacturers.
INREBIC Trademark Registration for Pharmaceutical Preparations
USPTO registered trademark TM86690908 for INREBIC on March 30, 2026. The mark covers pharmaceutical preparations for treatment of beta thalassemia, myelodysplastic syndromes, blood diseases, cancer, and cytokine inhibitory drugs. Originally filed July 13, 2015.
VIAFILL trademark renewal for bone void fillers
USPTO renewed the VIAFILL trademark (TM90272233) for bone void fillers consisting of biological materials. The trademark was originally filed on October 22, 2020. Trademark holders should ensure their IP portfolios remain current through periodic renewals.
Curagen Trademark Application - Wound Dressings
USPTO published trademark application TM99206605 for "CURAGEN" covering adhesive bandages for skin wounds, wound dressings, and medical/surgical dressings. The application was filed May 28, 2025 and published March 30, 2026. The trademark covers Class 10 medical devices for wound care.
Recall of Veos-Kaphron Polyaxial Screwdrivers - Distimp Spinal Equipment
ANSM has issued safety alert R2608136 for a recall of 847 units of Veos-Kaphron polyaxial screwdrivers manufactured by Distimp. This spinal ancillary equipment recall is a mandatory action to remove potentially defective medical devices from use in healthcare facilities. All affected users have received direct notification from Distimp regarding the recall procedures.
Recall of Dental Root Canal Instruments - Shenzhen Perfect Medical
ANSM issued safety recall R2606807 for dental root canal instruments manufactured by Shenzhen Perfect Medical Instruments Co., Ltd. The recall involves a lot withdrawal due to identified safety concerns. Healthcare facilities, dentists, and medical professionals using these instruments must identify and remove affected products from use.
Orbis Medication 3.x Safety Notice - DH Healthcare
ANSM informed healthcare facilities of a safety action (n° R2607882) implemented by DH Healthcare GmbH regarding Orbis Medication 3.x, a computer-aided prescribing software. Users have received direct correspondence from the manufacturer. Healthcare providers using this software should review the attached safety communication.
MarClamp Cut IQ Safety Notice - KLS Martin Group
ANSM issued safety notice R2608256 regarding KLS Martin Group's MarClamp Cut IQ electrosurgical device with instrument coding 23cm. Hospital pharmacies and healthcare establishments are directed to review and act upon the attached manufacturer safety communication. This is a Class I medical device safety action.
GE Healthcare Signa Premier MRI Safety Notice
ANSM informed health facilities and medical imaging centers of a safety action by GE Healthcare regarding the Signa Premier MRI system. The action is registered under reference R2608457. Healthcare providers who received the letter should review and implement the specified safety measures.
Oxoid Salmonella 9-0 Recall - Remel/Thermo Fisher Scientific
ANSM issued safety notice R2608613 informing medical biology laboratories of a field safety corrective action by Remel/Thermo Fisher Scientific, involving the recall of 847 units of Oxoid Salmonella agglutinating sera (Salmonella 9-0). Affected users received a direct communication from Thermo Fisher Scientific with instructions. Laboratories should verify their inventory for affected lots and contact the manufacturer directly.
Saudi launches food composition database, empowering nutrition awareness
The Saudi Food and Drug Authority (SFDA), through its National Nutrition Committee, launched the Saudi Food Composition Database in collaboration with the Health Sector Transformation Program. The database provides comprehensive nutritional profiles for traditional Saudi foods and local dishes, including calories, macronutrients, vitamins, and minerals. This initiative aligns with Saudi Vision 2030's goals for digital transformation of health and food sectors.
Vanda patents trichostatin A cancer treatment method
USPTO granted patent US12590162B2 to Vanda Pharmaceuticals Inc. covering a method of treating cancer using trichostatin A (TSA). Inventors include Mihael H. Polymeropoulos, Louis William Licamele, and Christian Lavedan. The patent contains 5 claims.
siRNA Septicemia Treatment Patent
USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.
Fusion antibody for presenting antigen-derived T cell epitope
USPTO granted Patent US12590156B2 to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a fusion antibody composition designed to deliver viral antigen-derived CD8+ T cell antigen epitopes to target cell cytoplasm for presentation on major histocompatibility complex class I (MHC-I) molecules. The patent contains 22 claims covering the composition and its use in antigen presentation.
1135 Waiver Request Automated Process PRA Information Collection
CMS published a 60-day Federal Register notice announcing an opportunity for public comment on a revision to the Submission of 1135 Waiver Request Automated Process information collection (OMB Control No. 0938-1384). The collection supports the Acute Hospital Care at Home (AHCAH) program. Comments must be submitted by June 1, 2026.
Polymorph of EP4 receptor antagonist, preparation method and use
USPTO granted patent US12590103B2 to Shanghai Yuyao Biotech Ltd. for a stable polymorph of an EP4 receptor antagonist. The patent covers the solid-state form with improved stability over the amorphous compound, with claims directed to oncology, immunology, and bone disease applications.
Corrosion inhibitor formulations with pyridinium and hydroxy substituents
The USPTO granted patent US12590256B2 to Saudi Arabian Oil Company on March 31, 2026, covering corrosion inhibitor formulations containing compounds with both pyridinium and hydroxy substituents. The patent includes 6 claims and covers methods of making the compounds and processes for inhibiting corrosion on metallic surfaces. Inventors include Muhammad Imran Ul-haq, Nayef M. Alanazi, Turki M. Al Abeedi, Abdullah Al-Malki, and Faisal M. Al-Mutahhar.
Spiromacrocyclic orexin 2 receptor agonists
USPTO granted Patent No. US12590106B2 to H. Lundbeck A/S for novel spiromacrocyclic orexin 2 receptor agonists used in CNS treatments. The patent, covering 18 claims, names 11 inventors including Karsten Juhl, Wanwan Yu, and Thomas Leegaard Andersen, with application originally filed as EP19195185.
KRas G12C inhibitors for cancer treatment
The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.
CD30+ Cancer Detection and Treatment Methods Patent
USPTO granted Patent US12590968B2 to Seagen Inc. for methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers. The patent (Kind B2), with inventors Tina Albertson and Maria L. Smith, contains 4 claims covering CPC classifications A61K 47/6849, C07K 16/2878, and A61P 35/00. Application No. 17747591 was filed May 18, 2022.
Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
USPTO granted Regeneron Pharmaceuticals Patent No. US12590168B2 covering CD38/CD28 bispecific antibodies designed to activate T-cells and inhibit tumor growth. The patent includes 35 claims and covers methods for treating cancers including multiple myeloma, lymphoma, and leukemia using bispecific antigen-binding molecules.
Combination therapies against cancer targeting CD38 and TGF-β
USPTO granted Sanofi Patent US12590167B2 covering combination cancer therapies targeting CD38 and TGF-β using specific antibodies. The patent (11 claims) was granted March 31, 2026, with a filing date of July 10, 2019. This patent relates to compositions and methods for treating cancer using dual-antibody therapy.
Fezolinetant (Veoza) for Menopause Vasomotor Symptoms
NICE published technology appraisal guidance TA1143 recommending fezolinetant (Veoza) as an option for treating moderate to severe vasomotor symptoms associated with menopause. The guidance applies to women who have had a breast cancer diagnosis where hormone replacement therapy is contraindicated. NHS commissioners must make funding available within 3 months of publication date.
Monthly Drug and Medical Device Safety Roundup
MHRA published its monthly safety roundup for March 2026, consolidating alerts on medicines and medical devices. The roundup includes multiple drug and device batch recalls affecting various therapeutic areas. Healthcare providers and patients should review the specific alerts to identify affected products in their supply chain or treatment.
Clinical Investigations in Northern Ireland for Medical Devices
MHRA published guidance clarifying clinical investigation requirements for medical devices in Northern Ireland under the EU Medical Device Regulation (EU MDR) 2017/745 and In Vitro Diagnostic Medical Device Regulation (EU IVDR) 2017/746. Manufacturers must notify MHRA when using non-UKCA or non-CE marked devices on human participants. The guidance establishes that a single EU MDR application covers sites in both Northern Ireland and Great Britain.
Clinical investigations for medical devices
MHRA published guidance explaining requirements for clinical investigations of medical devices in Great Britain under the UK MDR 2002. Manufacturers must notify MHRA of planned investigations involving non-UKCA or non-CE marked devices on human participants unless an exemption applies. The guidance clarifies different regulatory pathways for Great Britain versus Northern Ireland.
GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof
USPTO granted patent US12590134B2 to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. for a GLP-1 agonist polypeptide compound (SEQ ID NO: 1) used in diabetes and obesity treatment. The patent includes 2 claims covering the compound, salt forms, synthesis method, and therapeutic applications. Filing date was August 17, 2022, under application number 17820251.
Bi-specific Chimeric Antigen Receptor for TGF-beta Binding
USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026, covering a bi-specific chimeric antigen receptor (CAR) that specifically binds TGF-beta. The CAR technology neutralizes TGF-beta while simultaneously triggering T-cell activation, converting an immunosuppressive signal into an activating stimulus. The patent contains 10 claims with application number 17323568, filed May 18, 2021.
CD3-specific binding molecules
The USPTO granted Immunocore Limited Patent US12590152B2 covering CD3-specific binding molecules, specifically antibodies and fragments with improved properties. The patent contains 19 claims and names 8 inventors including Martina Canestraro and Stephen Harper. This is a routine patent grant establishing intellectual property rights without regulatory compliance obligations.
PD-L1 Binding Molecules and Uses Thereof
USPTO granted Patent US12590155B2 to Beijing Mabworks Biotech Co., Ltd. for molecules (single-domain antibodies and heavy chain only antibodies) that specifically bind human PD-L1 for use in treating tumors and related diseases. The patent contains 17 claims and covers the分子的 therapeutic applications in cancer treatment.
EGFR Bispecific Antibody Patent Grant - Amunix Pharmaceuticals
The USPTO granted patent US12590159B2 to Amunix Pharmaceuticals covering compositions targeting EGFR, including protease-activatable bispecific fusion proteins such as T cell engagers. The patent includes 8 claims for antibody binding domains targeting CD3 and EGFR, cleavable linker sequences, and methods of treatment for conditions such as cancer.
Anti-C-MPL antibody and use thereof
USPTO granted patent US12590161B2 to Daegu Gyeongbuk Institute of Science and Technology for an anti-C-MPL antibody (2R13) that increases platelet production through megakaryocyte maturation. The antibody offers longer half-life than conventional therapeutic agents with lower self-antibody production and reduced immunogenicity. The patent covers therapeutic applications for chronic or complication-induced immune thrombocytopenia.
Antibodies binding to citrullinated histone 2A and/or 4
USPTO granted Patent No. 12,590,143 B2 to Citryll B.V. for antibodies binding to citrullinated histone 2A and/or 4, covering therapeutic applications for Neutrophil Extracellular Trap (NET)-associated pathologies. The patent includes 13 claims and covers both the antibodies and binding fragments for use in treatment.
Anti-Henipavirus Monoclonal Antibodies with Broad Spectrum Neutralization
The USPTO granted Patent US12590141B2 to the Academy of Military Medical Science covering monoclonal antibodies targeting Henipavirus glycoprotein G. The patent claims antibodies combining macaque variable regions with human constant regions, demonstrating broad neutralization activity against Nipah and Hendra viruses. The patent includes 9 claims and covers encoding nucleic acids for therapeutic applications.
GLP-1/GIP Dual Agonist Patent for Diabetes Treatment
USPTO granted patent US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. for long-acting GLP-1/GIP dual agonist compounds for treating Type II diabetes mellitus. The patent covers compounds with dual agonistic effects on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors.
Benzimidazole and Benzimidazolone Based PROTAC Compounds for LRRK2 Degradation
The USPTO granted Arvinas Operations, Inc. patent US12589156B2 covering benzimidazole and benzimidazolone PROTAC compounds designed to recruit LRRK2 protein to E3 ubiquitin ligase for targeted degradation. The patent contains 12 claims and was filed on March 24, 2025.
Use of D9-methadone for postoperative pain relief
USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.
Gilead PD-1/PD-L1 inhibitors, cancer treatment compounds
USPTO granted Gilead Sciences, Inc. Patent US12590062B2 for PD-1/PD-L1 inhibitor compounds for cancer treatment. The patent covers compounds according to formula (I), methods of using said compounds singly or in combination with additional agents, and compositions for treating cancer. Application No. 17098171 was filed November 13, 2020, and the patent contains 18 claims.
Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases
USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.
Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar
Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar
Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof
USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.
Antiviral agents and uses thereof
The USPTO granted Patent US12590092B2 to Griffith University for antiviral compounds of Formula (I) and pharmaceutical compositions for treating viral infections. The patent, with 21 allowed claims, names Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, and Larissa Heilig as inventors. Filing date was January 28, 2022.
Substituted Entecavir Monophosphate Alaninamide Phenolic Esters for Hepatitis B
The USPTO granted Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. on March 31, 2026, covering entecavir monophosphate alaninamide phenolic ester derivatives for hepatitis B treatment. The patent grants exclusive rights to the pharmaceutical compound for resisting hepatitis B virus. This is a routine patent grant notification.
Spiroindoline pyrrolopyrrole triones NRF2-β-TrCP inhibitors for fatty liver treatment
USPTO granted Patent US12590100B2 to researchers from Universidad Autonoma de Madrid and CSIC for spiroindoline pyrrolopyrrole trione compounds that inhibit the NRF2-β-TrCP interaction for treating fatty liver disease. The patent covers 3 claims and relates to therapeutic applications for chronic inflammation and oxidative stress-related liver conditions.
Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
USPTO granted Patent US12590099B2 to Merck Sharp & Dohme LLC covering HDAC (histone deacetylase) inhibitors useful for treating or preventing HIV infection. The patent protects compounds of Formula I, pharmaceutical compositions thereof, and methods of treatment. Four claims were granted. The patent application was filed on November 4, 2019.
Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same
The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.
Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment
USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.
Crystalline Forms of Orally Available Selective KIT and PDGFR Kinase Inhibitor
USPTO granted patent US12590095B2 to Sandoz AG on March 31, 2026, covering crystalline forms of avapritinib, a KIT and PDGFR kinase inhibitor. The patent (CPC C07D 487/04) protects polymorphs and hydrates of the compound for treating gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Inventors include Verena Adamer, Andrea Thaler, and Erwin Schreiner.
Compounds for the treatment of neurodegenerative and metabolic disorders
USPTO granted Patent US12590094B2 to University of Florida Research Foundation for heterocyclic compounds targeting neurodegenerative diseases linked to protein misfolding, including Alzheimer's, Parkinson's, ALS, and prion diseases, as well as metabolic disorders. The patent covers 8 lead compound series demonstrating NAD-restoring properties and therapeutic efficacy in cellular and animal models.
Foghorn Therapeutics Patent for Heterocyclic Compounds Treating BAF Disorders
The USPTO granted patent US12590079B2 to Foghorn Therapeutics Inc. on March 31, 2026, covering heterocyclic compounds useful for treating BAF complex-related disorders. The patent names inventors Sabine K. Ruppel, Zhaoxia Yang, and Jason T. Lowe, with claims encompassing 20 compound variations classified under CPC codes C07D 401/14, C07D 471/04, C07D 471/10, and C07D 487/04.
Heterocyclic compound for organic electroluminescent elements
USPTO granted Patent US12590076B2 to Idemitsu Kosan Co., Ltd. for a heterocyclic compound represented by formula (1) used in organic electroluminescent elements. The patent, filed on May 10, 2019 (Application No. 17053630), contains 26 claims and covers compounds classified under CPC codes including C07D 307/91 and H01L 51/0052.
Fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment
USPTO granted Patent US12590081B2 to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment. The patent covers 21 claims for compounds, preparation methods, and pharmaceutical compositions containing the derivatives.
Gilead Sciences patent for toll-like receptor modulator compounds
USPTO granted Patent US12590089B2 to Gilead Sciences covering methods for preparing toll-like receptor modulator compounds. The patent, naming 12 inventors including Andrea Ambrosi and Pavel R. Badalov, contains 7 claims relating to (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or salts thereof. Application No. 17673141 was filed February 16, 2022.
Pyrimidine-Nitrogen Bicyclic IRAK-4 Inhibitor Compound Patent
USPTO granted patent US12590090B2 to Asahi Kasei Pharma Corporation covering pyrimidine-and nitrogen-containing bicyclic compounds with IRAK-4 inhibitory activity. The patent, with 35 claims filed on September 30, 2020, protects compounds useful for prophylactic and therapeutic treatment of diseases relating to IRAK-4 inhibition.
JAK Inhibitor Compound and Pharmaceutical Composition Patent
USPTO granted Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, covering a JAK inhibitor compound and pharmaceutical composition. The patent claims 4 items related to compounds of Formula I and their use in treating inflammatory, autoimmune, myeloproliferative diseases, and human cancers by regulating JAK kinase signal transduction.
GPR139 Antagonist Patent for Depression and Neurological Disorders
USPTO granted Takeda Pharmaceutical Company Limited Patent US12590086B2 for GPR139 antagonist compounds (3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives) used in methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and ADHD. The patent contains 27 claims and includes tablet formulations.
Oxadiazole HDAC6 inhibitors and uses thereof
The USPTO granted Patent US12590084B2 to Eikonizo Therapeutics, Inc. covering oxadiazole compounds that selectively inhibit HDAC6, a protein linked to cancer and neurological disorders including Alzheimer's disease. The patent includes 20 claims and covers pharmaceutical compositions and methods of treating HDAC6-related diseases. Inventors are Florence Fevrier Wagner and Thomas Edward Richardson.
SPNS2 inhibitors patent granted to University of Virginia
USPTO granted patent US12590083B2 to the University of Virginia Patent Foundation covering SPNS2 (spinster homolog 2) inhibitor compounds and their pharmaceutical compositions for therapeutic use. The patent, with 2 claims, protects Formula I compounds and methods of treatment using these inhibitors.
Fused tricyclic drug patent granted, Mar 31
Fused tricyclic drug patent granted, Mar 31
Acetohydroxy acid synthase variant and microorganism including the same
USPTO granted patent US12590128B2 to CJ CheilJedang Corporation on March 31, 2026, for an acetohydroxy acid synthase variant, polynucleotides encoding it, microorganisms containing it, and a method for producing L-isoleucine using the microorganism. The patent has 20 claims.
Bipartite molecules treating neurodegenerative diseases
USPTO granted Patent US12590130B2 to Academia Sinica for bipartite molecules comprising a peptide affinity moiety and charged moieties for treating neurodegenerative diseases associated with abnormal protein aggregates. The patent contains 6 claims and was granted March 31, 2026, with original filing date November 27, 2020. No compliance deadlines are associated with this patent grant.
Split PYP Complementation System for Detecting Protein Interactions
USPTO granted patent US12590127B2 to PARIS SCIENCES ET LETTRES for a split photoactive yellow protein (PYP) complementation system for detecting protein interactions. The patent covers two PYP fragments with at least 70% sequence identity to SEQ ID NO:23 and SEQ ID NO:34, used with fluorogenic HBR analogs for protein interaction detection. The grant includes 19 allowed claims.
Peptide with Neutralizing Activity Against SARS-CoV-2
The USPTO granted patent US12590124B2 to CAREGEN CO, LTD. for a peptide composition that specifically recognizes and neutralizes SARS-CoV-2. The patent covers both therapeutic applications for preventing or treating COVID-19 infection and diagnostic applications for detecting the virus. The patent contains 13 claims and lists 6 inventors.
Protease Inhibitor Compounds for Treating Cancer, Viral Infections, and Allergic Conditions
USPTO granted patent US12590123B2 to Washington University covering protease inhibitor compounds useful for treating coronaviruses, cancer, and allergic conditions. The patent discloses compounds inhibiting S1 serine proteases (HGFA, matriptase, hepsin, KLK5, TMPRSS2) and cysteine proteases with 10 claims. Filing date was June 25, 2020, with application number 17620169.
NRP-1 binding inhibitory peptides and uses thereof
USPTO granted patent US12590122B2 to INSERM for NRP-1 binding inhibitory peptides with anti-angiogenic properties for cancer treatment. The patent covers novel peptide-like compounds with nanomolar affinity for NRP-1 that inhibit VEGF-A165/NRP-1 interaction, representing an improvement over the prior A7R heptapeptide. Application 17618233 (filed June 10, 2020) contains 15 claims.
Materials and Methods for Isolating Self-Antigen Polypeptides
The USPTO issued Patent Grant US12590120B2 to Impact Proteomics covering materials and methods for isolating self-antigen polypeptides. The patent names inventors Jonathan Minden and Dana Ascherman and contains 19 claims. This grant confers exclusive rights to the patented technology for the patent term.
UFABC patents KLK7 antibodies, skin desquamation, 31st Mar
UFABC patents KLK7 antibodies, skin desquamation, 31st Mar
Treatment of cachexia using fibroblast cells and products thereof
USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.
Phenylethynyl-thiophene compounds for treating degenerative disorders
The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.
Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
The USPTO granted Patent US12589140B2 to The Brigham and Women's Hospital, Inc. covering methods for generating immune responses to cancer or infection by promoting differentiation of neutrophils into dendritic cells using GMCSF combined with immune complexes or anti-FcγRIIIB antibodies. The patent contains 14 claims and lists Tanya Mayadas, Vijaya Mysore, Xavier Cullere, and Jon C. Aster as inventors.
DNA Vaccine for Treating and Preventing Type 1 Diabetes
USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.
Viral vectors with RDH12 coding regions for treating retinal dystrophies
The USPTO granted Patent US12589136B2 to The Regents of the University of Michigan covering viral vectors comprising RDH12 coding regions and methods of using such vectors to treat retinal dystrophies, including Leber Congenital Amaurosis. The patent, with 12 claims, names Debra A. Thompson, Robin R. Ali, and Alexander J. Smith as inventors. The patent covers nucleic acids encoding human RDH12 protein and their use in gene therapy applications for ophthalmological conditions caused by loss-of-function mutations.
Aloe vera polysaccharide antimicrobial composition patent grant
USPTO granted Patent US12589130B2 to 2QR RESEARCH B.V. on March 31, 2026. The patent covers Aloe vera polysaccharide compositions with antimicrobial aggregating activity, having molecular weight of 30-100 kDa and comprising 80-100% w/w mannose. Inventors are Floris Koumans and Paul Kwakman. The patent has 14 claims.
Bacteriophages for treatment of tuberculosis
USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.
Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases
USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.
NOVOSEVEN Registered Trademark for Factor VIIa Hemophilia Treatment
USPTO has registered the trademark NOVOSEVEN (Registration No. TM74546941) for a Factor VIIa pharmaceutical preparation used in hemophilia treatment. The trademark was registered on March 30, 2026, with an original filing date of July 7, 1994. This is an informational trademark registration notice with no new compliance requirements.
Multivalent HVT vector vaccine for poultry
USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.
HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas
The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.
Peptide-derived KDM5C targeting cancer therapeutics patent grant
USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.
C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds
USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.
Regeneron cyclodextrin protein drug conjugates
USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.
Plasma kallikrein inhibitor patent for ocular disorders
The USPTO granted BioCryst Pharmaceuticals patent US12589093B2 covering plasma kallikrein inhibitor compositions for treating ocular disorders. The patent claims avoralstat-based drug compositions delivered via suprachoroidal space injection. The patent contains 16 claims and names inventors Yarlagadda Babu, Viral Kansara, and Rick McElheny.
Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK
Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK
Ruxolitinib formulation for reduction of itch in atopic dermatitis
USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.
Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted
USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.
Injectable sustained-release formulations for treatment of joint pain and inflammation
USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.
ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury
USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.
Method of fixating carbon dioxide to substituted oxazolidinones using MOF technology
USPTO granted patent US12590074B2 to King Fahd University of Petroleum and Minerals on March 31, 2026. The patent covers a method of fixating carbon dioxide (CO2) to form substituted oxazolidinones using a MIL-68(In)-X metal-organic framework (MOF) catalyst, reacting CO2 with epoxides and aromatic amines. The patent contains 20 claims and application number 18329092.
Process for preparation of macrocyclic chelant and metal complexes
USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.
Hydrazone derivative with aryl-substituted terminal amine group and use thereof
USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.
Adamantane derivatives as inhibitors of focal adhesion kinase
USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026, covering novel adamantane derivatives as inhibitors of focal adhesion kinase (FAK) for pharmaceutical use. The patent includes 17 allowed claims and covers compounds, salts, stereoisomers, and pharmaceutical compositions. The invention is classified under CPC codes including C07D 239/48, C07D 401/12, and A61P 35/00 (antineoplastic agents).
Crystalline salts of plasma kallikrein inhibitor patent grant
USPTO granted BioCryst Pharmaceuticals, Inc. Patent US12590068B2 covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, and related pharmaceutical preparations. Inventors: Yahya El-Kattan and Yarlagadda S. Babu. The patent contains 30 claims and 3 CPC classifications (C07D 231/14, A61K 9/0029, C07B 2200/13).
Thyromimetics Patent - Autobahn Therapeutics
USPTO granted patent US12590072B2 to Autobahn Therapeutics, Inc. covering thyromimetic compounds for treating neurodegenerative disorders and fibrotic diseases. The patent (20 claims) names inventors Thomas von Geldern and Bradley Backes, with original filing date June 17, 2021. This is a routine patent grant notice with no compliance obligations.
Crystalline Salts of Plasma Kallikrein Inhibitor Patent
USPTO granted patent US12590069B2 to BioCryst Pharmaceuticals, Inc. covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, pharmaceutical preparations, and methods of treatment. The patent (30 claims) names inventors Yahya El-Kattan and Yarlagadda S. Babu, with an August 28, 2025 filing date. This is a routine patent grant establishing intellectual property protection with no new regulatory compliance obligations.
COVID-19 Vaccine Antigen Composition Data Request for May 2026
WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued updated guidance requesting vaccine manufacturers submit immunological, virological, and vaccine effectiveness data ahead of the May 2026 decision-making meeting. The statement updates previous September 2025 guidance and specifies key antisera and antigens of interest including JN.1, KP.2, XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 variants. Manufacturers should submit both pre- and post-vaccination antisera analysis for neutralization testing.
Diaminoguanidine derivative treats bacterial infections in farmed animals
USPTO granted patent US12589085B2 to Guangzhou Insighter Biotechnology Co., Ltd. for a diaminoguanidine derivative compound and feed composition for veterinary use in preventing and treating bacterial infections in farmed animals. The patent covers the compound with R1 as C1-C20 alkyl, applications including reproductive system and skin infections, and includes 11 claims.
CD80 Extracellular Domain Fc Fusion Proteins for Treating PD-L1 Negative Tumors
The USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. covering fusion proteins combining the CD80 extracellular domain with the Fc domain of IgG1 for treating PD-L1 negative tumors. The patent includes 22 claims and names Susannah D. Barbee, Thomas Brennan, and Barbara Sennino as inventors. This grant establishes exclusive rights for the assignee in this therapeutic application.
Method for producing modified pea protein
USPTO granted patent US12588686B2 to Ajinomoto Co., Inc. covering methods for producing modified pea protein with improved solubility. The method involves treating pea ground product with acid and conducting enzyme reactions using protein deamidase. The patent contains 4 claims and names three inventors.
177Lu peptide targets uPAR receptor for colorectal cancer treatment
USPTO granted patent US12589171B2 to TRT INNOVATIONS APS covering a 177-Lu labeled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for treatment of cancers with high uPAR expression, particularly colorectal cancer. The patent includes 9 claims and lists inventors Andreas Kjaer, Morten Persson, and Michael Ploug.
Root-knot Nematode Resistance Gene Patent Grant
USPTO granted patent US12588644B2 to Rijk Zwaan Zaadteelt En Zaadhandel B.V. covering a nucleic acid encoding the MeR1 protein that confers resistance to root-knot nematode in Solanaceae plants. The patent includes 18 claims covering the gene sequences, amino acid sequences, and methods of using the resistance gene in plant breeding. The inventors are Raoul Jacobus Johannes Maria Frijters, Jonathan Kalisvaart, and Adriaan Verhage.
Otoferlin Dual Vector Systems for Treating Sensorineural Hearing Loss
The USPTO granted Regeneron Pharmaceuticals Patent US12589168B2 for compositions and methods treating sensorineural hearing loss using otoferlin (OTOF) dual vector gene therapy systems. The patent covers a two-vector approach delivering N-terminal and C-terminal portions of OTOF isoform 5 to restore gene function in patients with OTOF mutations. Application No. 17733744 was filed April 29, 2022.
Production of antibodies by modification of autonomous heavy chain variable domain via gene conversion
USPTO granted patent US12588664B2 to Crystal Bioscience Inc. on March 31, 2026. The patent covers transgenic animals engineered with B cells that use gene conversion for antibody diversification, involving functional immunoglobulin heavy chain genes and operably linked pseudogenes that donate sequence to enable diversification.
Cerebrolysin patent for CADASIL treatment
USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH for a method of using cerebrolysin to reduce mortality in patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). The patent includes 15 claims and was filed on August 28, 2018.
Levorphanol prodrugs and processes for making and using them
The USPTO granted Patent US12590065B2 to Zevra Therapeutics, Inc. covering novel levorphanol prodrug compositions formed by chemically conjugating oxoacids, polyethylene glycols, or vitamin compounds to levorphanol. The patent includes claims to the compositions and methods of making and using them.
Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof
USPTO granted Patent US12590066B2 to Korea Institute of Science and Technology for novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds. The patent includes 20 claims and names inventors Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Haeun Lee, Woo Seung Son, and Hye Yeon Lee. The compounds have potential pharmaceutical applications.
Process for the production of levetiracetam
USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.
Information Collection Request Comment Notice
CMS published a Federal Register notice announcing a 60-day public comment period on a proposed information collection (CMS-10752) under the Paperwork Reduction Act. The collection relates to Medicare and Medicaid program information gathering. Comments must be received by June 1, 2026.
Digital Health Technologies in Clinical Investigations - Request for Comments
FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have issued a Request for Information on the use of Digital Health Technologies (DHTs) in clinical investigations for drugs and biological products. The agency seeks stakeholder input on opportunities, challenges, and best practices before potential future regulatory activities. Comments are due June 1, 2026.
FDA Decision Denying Hearing Request on TRADIPITANT Approval Refusal
The FDA issued a decision denying Vanda Pharmaceuticals' request for a hearing regarding CDER's proposal to refuse approval of NDA 218489 for TRADIPITANT capsules (85 mg) for the treatment of gastroparesis symptoms. The decision upholds the complete response letter issued September 18, 2024, and the Notice of Opportunity for Hearing published January 16, 2025 (90 FR 4748).
NIH Center for Scientific Review closed meetings, 31st Mar
NIH Center for Scientific Review closed meetings, 31st Mar
Notice of Closed Meetings for Grant Application Reviews
The NIH Center for Scientific Review published a Federal Register notice announcing five closed meetings scheduled for April 20-24, 2026, pursuant to section 1009 of the Federal Advisory Committee Act. The meetings will review grant applications including the MIST (U01) program, Health Services Career Development Awards, and various biomedical research topics. Meetings are closed under Government in the Sunshine Act exemptions to protect confidential trade secrets and personal privacy.
Medical Expenditure Panel Survey Household Component Comment Request
AHRQ published a 30-day comment request notice for the Medical Expenditure Panel Survey (MEPS) Household Component (OMB No. 0935-0118). The survey collects data on health services usage, costs, and insurance coverage. Comments must be submitted by April 30, 2026.
Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Black Lung Clinics Program Performance Measures, OMB No. 0915-0292-Revision
HRSA requests public comment, Black Lung Clinics Program
Magic Eyes Trademark - Sexual Lubricants and Sex Toys
The USPTO renewed Trademark TM87136624 for "Magic Eyes" covering personal sexual lubricants, love dolls, and sex toys. The registration was renewed on March 29, 2026, extending protection for goods in International Class 005. Original filing date was August 12, 2016.
MEDICHOICE Trademark Registration for Medical Products
USPTO registered trademark TM76352417 for MEDICHOICE covering a broad range of medical and surgical products and supplies. The trademark covers goods including disposable medical apparel, surgical instruments, patient examination equipment, and various medical supplies. The original filing date was December 26, 2001.
Flucelvax Quadrivalent Influenza Vaccine Trademark Renewal
The USPTO renewed trademark registration TM87135582 for "Flucelvax Quadrivalent," an influenza vaccine for human use. The renewal was granted on March 29, 2026, extending the trademark protection for the pharmaceutical product branding originally filed on August 11, 2016.
SALONPAS HOT Trademark Renewal
The USPTO renewed trademark registration TM87144971 for SALONPAS HOT pain relief patches on March 29, 2026. The trademark covers medicated transdermal patches and plasters for relief of muscle and joint aches. This is a routine administrative renewal confirming continued trademark protection.
INJURECOV Trademark Renewal
USPTO renewed trademark TM87144175 for INJURECOV, covering herbal supplements in Class 005 (pharmaceuticals). The trademark was originally filed on August 19, 2016 and has been renewed for another registration period. This is a routine administrative trademark renewal with no new obligations.
Bio Products Laboratory Rabies Immunoglobulin Batch Recall - Reduced Potency
MHRA issued a Class 2 medicines recall for Bio Products Laboratory Limited's batch JRC24208 of Rabies Human Normal Immunoglobulin 500IU solution for injection due to stability failure causing reduced potency. Approximately 1,414 packs distributed since October 2024 are affected, expiring April 2027. Healthcare professionals must immediately quarantine and return the affected stock. No adverse events have been reported.
Overtime and Holiday Inspection Fee Reductions for Small and Very Small Establishments
The Food Safety and Inspection Service (FSIS) announced a temporary fee reduction program for FY 2026 using $20 million in de-obligated funds from the Meat and Poultry Processing Expansion Program. Small establishments will receive a 30% reduction and very small establishments will receive a 75% reduction on overtime and holiday inspection fees. Eligible establishments must submit FSIS Form 5200-16 to qualify, with retroactive refunds available for fees paid since October 5, 2025.
Laboratory Assessment Requests Information Collection Renewal
FSIS is announcing the renewal of an approved information collection (OMB No. 0583-0183) for non-FSIS laboratories (state, local, or private) that test food samples during illness outbreak and recall investigations. There are no changes to the existing information collection requirements. The approval for this collection expires August 31, 2026. Public comments are requested by May 26, 2026.
Moxifloxacin ophthalmic solution recall due to assay out of trend
Health Canada issued a Type II recall for pms-MOXIFLOXACIN HCL 0.5% Ophthalmic Solution (DIN 02432218, Lot 240518) distributed nationally by Pharmascience. The recall was triggered because the assay is out of trend for the affected lot. Healthcare providers and consumers should verify if they have the affected product and consult with healthcare professionals before discontinuing use.